Welcome to our dedicated page for Becton Dickinson & news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & stock.
Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (NYSE: BDX) announced that it will report its financial results for the second quarter of fiscal year 2023 on May 4, 2023. The results will be available at approximately 6:30 a.m. ET and will include summary financial information for the quarter ending March 31, 2023. An audio webcast hosted by management will follow at 8 a.m. ET on the same day, discussing financial results, operations, and strategic updates. For access, visit BD's investor relations website. BD is recognized as a global leader in medical technology, committed to enhancing healthcare delivery.
On April 3, 2023, Becton, Dickinson and Company (NYSE: BDX) announced the appointment of Michelle Quinn as Executive Vice President and General Counsel, effective April 1. Quinn, who joined BD in 2019, previously served as Acting General Counsel and Senior Vice President. She will lead the Law Group and report to Tom Polen, CEO. Quinn's extensive experience in healthcare legal functions is expected to support BD's business strategies and governance initiatives. She holds a Juris Doctor from Villanova University and a Bachelor of Arts from Colgate University.
BD (NYSE: BDX) has received 510(k) clearance from the FDA for its BD Vaginal Panel on the BD COR™ System, a diagnostic test that detects the three most common causes of vaginitis using a single swab. This test improves detection accuracy for conditions like bacterial vaginosis and vulvovaginal candidiasis, ensuring proper treatment and helping reduce misdiagnoses. The BD Vaginal Panel is the first high-throughput version of its kind, further enhancing BD's commitment to women's health diagnostics. The BD COR™ System allows high-volume testing, significantly improving laboratory efficiency and patient management.
BD (Becton, Dickinson and Company) (NYSE: BDX) will present at the Barclays Global Healthcare Conference on March 15, 2023, at 9:00 am Eastern Time. The live webcast can be accessed via the BD investor relations website, with a replay available afterward. BD is a leading global medical technology company focused on improving health through innovative technologies and services. With a workforce of 77,000, BD collaborates globally to tackle critical health issues, enhance clinical processes, and foster efficient care delivery. For more information about BD, visit bd.com.
BD (Becton, Dickinson and Company), a top medical technology firm, will present at the Cowen 43rd Annual Healthcare Conference on March 6, 2023, at 9:50 AM Eastern Time. Investors can access the live webcast on BD's investor relations website. A replay will be available after the event. BD focuses on advancing healthcare with innovative technologies and services, supporting healthcare professionals in improving patient outcomes. With a global workforce of 77,000, BD addresses key health challenges through collaborations worldwide. For more details, visit bd.com.
BD (NYSE: BDX) has received FDA approval for its Onclarity™ HPV Assay, designed for use with the ThinPrep® Pap Test. This assay is uniquely capable of individually identifying a broader range of HPV types, including the high-risk HPV31, which significantly enhances the ability to assess cervical cancer risk. The Onclarity™ HPV Assay’s approval supports BD's strategy to grow in the molecular diagnostics market. It detects 14 high-risk HPV types, providing crucial insights for clinical decision-making. The assay is validated through a large real-world study, improving both screening efficacy and women’s health management.
Summary not available.
BD (NYSE: BDX) announced FDA Emergency Use Authorization for a new molecular diagnostic test that identifies SARS-CoV-2, Influenza A+B, and Respiratory Syncytial Virus (RSV). This test, designed for the BD MAX™ System, allows for rapid diagnosis using a single nasal or nasopharyngeal swab, with results available in as little as two hours. It aims to streamline testing during respiratory virus seasons and enhance clinical treatment strategies. The BD MAX™ System is already widely utilized across hospitals and laboratories, capable of analyzing hundreds of samples daily.
BD (NYSE: BDX) announced the launch of the BD Rhapsody™ HT Xpress System designed for single-cell multiomics analysis, enabling researchers to conduct high-throughput studies with improved sample integrity. This new system can analyze up to eight times more cells than previous models, allowing simultaneous analysis of various cell types like stem and cancer cells. The system will be showcased at the AGBT General Meeting from February 6-9, 2023, in Hollywood, Florida. Additionally, BD is introducing the BD Rhapsody™ Mouse TCR/BCR Multiomic Assay and BD® Flex Single-Cell Multiplexing Kits to enhance data collection capabilities.
BD (Becton, Dickinson and Company) reported first-quarter fiscal 2023 revenues of $4.6 billion, a 2.8% decline year-over-year, while base business revenue increased by 0.4%. Diluted EPS decreased to $1.70 from $1.90, and adjusted diluted EPS fell to $2.98 from $3.17. Despite these declines, the company raised its full-year revenue guidance to $19.1 billion - $19.3 billion and adjusted EPS to $12.07 - $12.32, indicating resilience and strong execution of its BD 2025 strategy. The outlook anticipates continued currency-neutral growth of 5.75% - 6.75% in its base business.